Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Defining the role of mTOR in cancer Guertin DA; Sabatini DMCancer Cell 2007[Jul]; 12 (1): 9-22The mammalian target of rapamycin (mTOR) has emerged as a critical effector in cell-signaling pathways commonly deregulated in human cancers. This has led to the prediction that mTOR inhibitors may be useful in oncology, and derivatives of one such molecule, rapamycin (from which mTOR derives its name), are currently in clinical development. In this review, we discuss recent progress in understanding mTOR signaling, paying particular attention to its relevance in cancer. We further discuss the use of rapamycin in oncology and conclude with a discussion on the future of mTOR-targeted therapy.|Antineoplastic Agents/pharmacology/therapeutic use[MESH]|Humans[MESH]|Neoplasms/drug therapy/metabolism/*physiopathology[MESH]|Phosphatidylinositol 3-Kinases/metabolism[MESH]|Protein Kinases/drug effects/*physiology[MESH]|Proto-Oncogene Proteins c-akt/metabolism[MESH]|Signal Transduction[MESH]|TOR Serine-Threonine Kinases[MESH] |